Clinical Trials

    Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

    Investigator: Shilpan Shah

    Study Coordinator: Danielle Sewall

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT05384587

    Phone: 346.238.2674

    Protocol Number: PRO00037739

    Description


    This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.